Status:
ENROLLING_BY_INVITATION
A Study of Ropivacaine Combined With Different Concentrations of Methylene Blue Fascia Iliaca Block in Postoperative Analgesia, Cognition, and Hip Function Recovery in Patients Undergoing Hip Arthroplasty
Lead Sponsor:
Wang wanxia
Conditions:
Femoral Neck Disease
Eligibility:
All Genders
60-85 years
Phase:
NA
Brief Summary
Total hip arthroplasty (THA) is a commonly used treatment for hip lesions, but it is often accompanied by persistent pain after surgery, which obviously affects the quality of life of patients, so per...
Eligibility Criteria
Inclusion
- Hip replacement surgery is indicated
- ASA Class II - Class III
- No history of analgesic or local anesthetic allergy
- No history of alcohol abuse or narcotic drug abuse
- Patients and their families have given informed consent and signed the informed consent form
Exclusion
- Patient or family refusal to participate in the study
- Severe coagulation abnormalities
- Local anesthetic allergy
- Severe psychiatric illness or other communication disorder
- There is an infection at the puncture site
Key Trial Info
Start Date :
March 15 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2024
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT06520306
Start Date
March 15 2024
End Date
August 31 2024
Last Update
July 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhang Yang
Taizhou, China